Proteomics

Dataset Information

0

Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer’s disease from tear fluid


ABSTRACT: Accurate diagnosis of Alzheimer’s disease (AD) in its earliest stage can prevent the disease and delay the onset of symptoms by maintaining a healthy lifestyle and controlling modifiable risk factors. Therefore, more sensitive, relatively inexpensive, non-invasive, and simple screening tools are required for the early diagnosis and progression monitoring of AD. Here, we designed a self assembled nanoparticle-mediated amplified fluorogenic immunoassay (SNAFIA) consisting of magnetic and fluorophore-loaded polymeric nanoparticles. Multiple simultaneous captures and magnetic separation of biomarkers and target-specific fluorophore emission induced a one-tomulti signal, resulting in a low detection limit (236 aM), good reliability (R2 = 0.991), and wide analytical range (0.320–1000 fM) for APOE and CAP1 biomarkers in human serum and tear fluid. More importantly, SNAFIA successfully differentiated AD patients from healthy controls with 90% sensitivity and 100% specificity in less than 1 h in 39 clinical tear samples. As an easily accessible diagnostic tool with fast and accurate results, SNAFIA can help diagnose AD early to aid in long-term care planning, increase the efficiency of clinical trials, and dramatically accelerate therapeutic development.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Tear

DISEASE(S): Alzheimer's Disease

SUBMITTER: Chae Eun Moon  

LAB HEAD: Yong Woo Ji

PROVIDER: PXD042142 | Pride | 2024-01-26

REPOSITORIES: Pride

altmetric image

Publications

Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer's disease from tear fluid.

Lee Sojeong S   Kim Eunjung E   Moon Chae-Eun CE   Park Chaewon C   Lim Jong-Woo JW   Baek Minseok M   Shin Moo-Kwang MK   Ki Jisun J   Cho Hanna H   Ji Yong Woo YW   Haam Seungjoo S  

Nature communications 20231209 1


Accurate diagnosis of Alzheimer's disease (AD) in its earliest stage can prevent the disease and delay the symptoms. Therefore, more sensitive, non-invasive, and simple screening tools are required for the early diagnosis and monitoring of AD. Here, we design a self-assembled nanoparticle-mediated amplified fluorogenic immunoassay (SNAFIA) consisting of magnetic and fluorophore-loaded polymeric nanoparticles. Using a discovery cohort of 21 subjects, proteomic analysis identifies adenylyl cyclase  ...[more]

Similar Datasets

2012-07-13 | E-GEOD-39341 | biostudies-arrayexpress
2020-08-20 | PXD020217 | Pride
2022-02-14 | PXD028811 | Pride
2022-05-31 | PXD033101 | Pride
2023-10-24 | PXD037811 | Pride
2016-12-13 | PXD003825 | Pride
2019-11-04 | PXD014475 | Pride
2019-11-12 | PXD008536 | Pride
2023-01-25 | PXD038280 | Pride
2021-12-20 | PXD028392 | Pride